Transmolecular Inc (AKA: TMI) Profile last edited on: 5/15/2019
CAGE: 4ZME8
UEI:
Business Identifier: Cancer treatment using synthetic versions of peptides isolated from natural products 
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
840 Memorial Drive Second Floor
Cambridge, MA 02139
Cambridge, MA 02139
| (617) 995-3050 |
| info@transmolecular.com |
| www.transmolecular.com |
Location: Multiple
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Public Profile
With corporate headquarters in Cambridge, MA., TransMolecular (TMI) TransMolecular, Inc. is a biotechnology company committed to discovering, developing, and commercializing novel, targeted therapies that promise to improve outcomes for gliomas, metastatic brain tumors, and other aggressive cancers with limited treatment options. Their SBIR awards were all received in AL. Focused to extending survival and preserve quality of life for millions of cancer patients by providing therapies and delivery technologies that exclusively target malignant cells while avoiding interaction with normal, healthy cells, the firm offered TM601, a synthetic a polypeptide based on amino acid peptide derived from scorpion venom, which is used to treat cancer. Organized around therapies for glioma, metastatic brain tumors, and cancers, in March 2011. Eisai Inc. and its Morphotek Inc. division - protein and antibody therapeutics for cancer, inflammation, and infectious diseases - acquired full rights to a proprietary tumor-targeting peptide (TTP) technology from TransMolecular Inc.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
50-74Revenue Range
5M-7.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
| Year | Phase | Agency | Total Amount | |
|---|---|---|---|---|
| 2003 | 2 | NIH | $882,996 | |
| Project Title: Nan Sodium Channel: Novel Target For Pain Drug Discovery | ||||
| 2000 | 1 | NIH | $131,702 | |
| Project Title: Chloride Channels: Novel Targets For Cancer Treatment | ||||
Key People / Management
Matthew A Gonda -- President
Vernon L Alvarez -- Vice President, Research & Development
Matthew D Carrington -- Director, Finance & Corporate Development
Diana M Hablitz -- Director, Preclinical and ClinicalDevelopment
Susan A Lyons
Vernon L Alvarez -- Vice President, Research & Development
Matthew D Carrington -- Director, Finance & Corporate Development
Diana M Hablitz -- Director, Preclinical and ClinicalDevelopment
Susan A Lyons
Company News
There are no news available.
